Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Elecoglipron

Phase 3

Elecoglipron is one of 38 therapeutic programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.

2

Indications

7

Total Trials

7

Active Trials

37

Competitors

Pipeline

Status by Indication[2][1]

Indication

Type 2 Diabetes MellitusNot yet recruiting

Weight ManagementNot yet recruiting

Type 2 Diabetes MellitusPhase 3

Not yet recruiting

Weight ManagementPhase 3

Not yet recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Byetta

Elecoglipron

Tanzeum

Adenocard

Dostinex

Cipro

Myrbetriq

Golytely

Lantus

Lixisenatide

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Study completion

NCT07534592

Q2 2028

Phase 3Not yet recruiting

Type 2 Diabetes Mellitus

NCT07664553

Phase 3Not yet recruiting

Type 2 Diabetes Mellitus

NCT07662213

Q3 2028

Phase 3Not yet recruiting

Type 2 Diabetes Mellitus

NCT07662109

Phase 3Not yet recruiting

Type 2 Diabetes Mellitus

NCT07662135

Phase 3Not yet recruiting

Type 2 Diabetes Mellitus

NCT07662044

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus5 trials

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)

Not yet recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07664553·600 enrolled

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)

Not yet recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07662109·2,000 enrolled

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)

Not yet recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07662213·1,200 enrolled

Show 2 more trials

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

Not yet recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07662135·900 enrolled

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)

Not yet recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07662044·800 enrolled

Weight Management1 trial

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07667803·4,500 enrolled

Unspecified1 trial

An Open-label, Fixed-sequence Study to Assess the Effect of Elecoglipron on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Participants

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07534592·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Elecoglipron. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Elecoglipron. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AstraZeneca

Related News